Ropes & Gray represented Spyre Therapeutics in a $316 million public offering of 17,094,594 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 2,229,729 additional shares at a public offering price per share of $18.50. The offering priced on October 13, 2025, and closed on October 15, 2025.
Spyre is a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of inflammatory bowel disease and other immune-mediated diseases.
The deal team was led by capital markets partner Tom Danielski and associate Emily Weiss-Cook.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.